U.S. markets close in 3 hours 31 minutes
  • S&P 500

    4,167.59
    +55.09 (+1.34%)
     
  • Dow 30

    34,322.49
    +301.04 (+0.88%)
     
  • Nasdaq

    13,390.40
    +265.41 (+2.02%)
     
  • Russell 2000

    2,213.15
    +42.20 (+1.94%)
     
  • Crude Oil

    65.12
    +1.30 (+2.04%)
     
  • Gold

    1,839.00
    +15.00 (+0.82%)
     
  • Silver

    27.46
    +0.40 (+1.48%)
     
  • EUR/USD

    1.2145
    +0.0060 (+0.50%)
     
  • 10-Yr Bond

    1.6370
    -0.0310 (-1.86%)
     
  • GBP/USD

    1.4098
    +0.0046 (+0.33%)
     
  • USD/JPY

    109.3700
    -0.0640 (-0.06%)
     
  • BTC-USD

    51,006.64
    +835.59 (+1.67%)
     
  • CMC Crypto 200

    1,424.99
    +66.43 (+4.89%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

Moderna to Present at the 20th Annual Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that David Meline, Chief Financial Officer, and Lavina Talukdar, Senior Vice President & Head of Investor Relations, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 15th, 2021 at 11:45 a.m. ET.

A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 13 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210409005066/en/

Contacts

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com